by Josh Friedman | Jul 7, 2025 | Uncategorized
Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis of individuals diagnosed with multiple myeloma showed that those who reported having “low” physical function, such as struggling to do...
by MM360 Staff | Jul 4, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by MM360 Staff | Jul 4, 2025 | Publications
Leukemia. 2025 Jul 2. doi: 10.1038/s41375-025-02677-5. Online ahead of print. ABSTRACT The cytogenetic abnormalities translocations t(4;14) and t(14;16) and the deletion of chromosome 17p in newly-diagnosed multiple myeloma are associated with poor disease prognosis...
by MM360 Staff | Jul 3, 2025 | Myeloma News
Source: Pharmacy Times articles The treatment becomes the first approved BCMAxCD3 bispecific antibody with the potential to achieve biweekly or monthly dosing in patients with relapsed/refractory multiple myeloma. Read More
by MM360 Staff | Jul 3, 2025 | Uncategorized
Source: CureToday articles The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program. Read More
